These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 17675264)

  • 1. Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis.
    Sancho JM; Deben G; Parker A; Piñana JL; Bolam S; Sánchez-García E; Giménez E; Pascual T; Fernández-Abellán P; Palomera L; Ribera JM
    Int J Hematol; 2007 Jul; 86(1):33-6. PubMed ID: 17675264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study.
    Sancho JM; Morgades M; Arranz R; Fernández-Abellán P; Deben G; Alonso N; Blanes M; Rodríguez MJ; Nicolás C; Sánchez E; Fernández de Sevilla A; Conde E; Ribera JM;
    Med Clin (Barc); 2008 Oct; 131(11):401-5. PubMed ID: 18928719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases.
    Sancho JM; Ribera JM; Romero MJ; Martín-Reina V; Giraldo P; Ruiz E
    Haematologica; 2006 Mar; 91(3):ECR02. PubMed ID: 16533729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis.
    Benesch M; Sovinz P; Krammer B; Lackner H; Mann G; Schwinger W; Gadner H; Urban C
    J Pediatr Hematol Oncol; 2007 Apr; 29(4):222-6. PubMed ID: 17414563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation.
    Hilgendorf I; Wolff D; Junghanss C; Kahl C; Leithaeuser M; Steiner B; Casper J; Freund M
    Ann Hematol; 2008 Dec; 87(12):1009-12. PubMed ID: 18704421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia.
    Sommer C; Lackner H; Benesch M; Sovinz P; Schwinger W; Moser A; Bergloeff J; Gruber A; Urban C
    Ann Hematol; 2008 Nov; 87(11):887-90. PubMed ID: 18575860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.
    Jabbour E; O'Brien S; Kantarjian H; Garcia-Manero G; Ferrajoli A; Ravandi F; Cabanillas M; Thomas DA
    Blood; 2007 Apr; 109(8):3214-8. PubMed ID: 17209054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flow cytometric detection of liposomal cytarabine in cerebrospinal fluid of patients treated with intrathecal chemotherapy.
    Stacchini A; Demurtas A; Aliberti S
    Cytometry B Clin Cytom; 2012 Sep; 82(5):280-2. PubMed ID: 22539249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments.
    Benesch M; Urban C
    Expert Opin Pharmacother; 2008 Feb; 9(2):301-9. PubMed ID: 18201152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of intrathecal liposomal cytarabine as central nervous system prophylaxis in patients with acute lymphoblastic leukemia.
    Valentin A; Troppan K; Pfeilstöcker M; Nösslinger T; Linkesch W; Neumeister P
    Leuk Lymphoma; 2014 Aug; 55(8):1739-42. PubMed ID: 24138308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia.
    Bassan R; Masciulli A; Intermesoli T; Audisio E; Rossi G; Pogliani EM; Cassibba V; Mattei D; Romani C; Cortelezzi A; Corti C; Scattolin AM; Spinelli O; Tosi M; Parolini M; Marmont F; Borlenghi E; Fumagalli M; Cortelazzo S; Gallamini A; Marfisi RM; Oldani E; Rambaldi A
    Haematologica; 2015 Jun; 100(6):786-93. PubMed ID: 25749825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis: efficacy and long-term safety in a single institution.
    Brion A; Legrand F; Larosa F; Schillinger F; Garnache-Ottou F; Helias P; Fontan J; Heczko M; Delaby P; Daguindau E; Vuillier J; Chauchet A; Deconinck E
    Invest New Drugs; 2012 Aug; 30(4):1697-702. PubMed ID: 21229289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity and efficacy of intrathecal liposomal cytarabine in children with leukemia/lymphoma relapsing in the central nervous system: a retrospective multicenter study.
    Parasole R; Petruzziello F; Messina C; Barisone E; Pession A; Locatelli F; Micalizzi C; Cesaro S; Testi AM; De Matteo A; Varotto S; Berger M; Morello W; Menna G; Poggi V
    Leuk Lymphoma; 2015 Mar; 56(3):650-5. PubMed ID: 24882262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial.
    González-Barca E; Canales M; Salar A; Ferreiro-Martínez JJ; Ferrer-Bordes S; García-Marco JA; Sánchez-Blanco JJ; García-Frade J; Peñalver J; Bello-López JL; Sancho JM; Caballero D;
    Ann Hematol; 2016 May; 95(6):893-9. PubMed ID: 27025508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine.
    Kripp M; Hofheinz RD
    Int J Nanomedicine; 2008; 3(4):397-401. PubMed ID: 19337408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers.
    Jurczak W; Kroll-Balcerzak R; Giebel S; Machaczka M; Giza A; Ogórka T; Fornagiel S; Rybka J; Wróbel T; Kumiega B; Skotnicki AB; Komarnicki M
    Med Oncol; 2015 Apr; 32(4):90. PubMed ID: 25716885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrathecal chemotherapy and meningeal relapses in myelomonocytic AML. A single institution experience.
    Romani C; Di Tucci AA; Dessalvi P; Pettinau M; Emanuele A
    Am J Hematol; 2010 Mar; 85(3):219. PubMed ID: 20063278
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study.
    Benesch M; Siegler N; Hoff Kv; Lassay L; Kropshofer G; Müller H; Sommer C; Rutkowski S; Fleischhack G; Urban C
    Anticancer Drugs; 2009 Oct; 20(9):794-9. PubMed ID: 19617818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience using intrathecal liposomal cytarabine to manage neoplastic meningitis in three patients with acute promyelocytic leukemia.
    Duarte RF; Arnan M; Sánchez-Ortega I; de Llano MP; Abellán PF
    Leuk Res; 2011 Jul; 35(7):e128-30. PubMed ID: 21501870
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.
    Chamberlain MC; Glantz MJ
    Blood; 2007 Sep; 110(5):1698; author reply 1698-9. PubMed ID: 17712051
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.